Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Madrigal Pharmaceuticals gains FDA approval for NASH medicine Rezdiffra

Madrigal Pharmaceuticals achieved FDA approval for Rezdiffra, focusing on market leadership and patient services.
Sales expected to be back-end loaded in 2024, with varying prescription dynamics and affordability considerations.
Company confident in revenue consensus but hasn't provided specific numbers, creating uncertainty for investors.
Emphasis on high unmet need, early positive feedback, and comprehensive patient support services.

Madrigal Pharmaceuticals excels in Q2 with Rezdiffra launch success

Madrigal Pharmaceuticals demonstrated strong financial performance and market acceptance of Rezdiffra in Q2 2024.
The company faces challenges in educating stakeholders and managing operational aspects of expansion.
Opportunities lie in global expansion, new market segments, and continued growth in sales and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Company to host conference call at 8:00 AM ET, May 9th, 2022

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anticipated to report data for the Phase 3 (MAESTRO-NASH) trial.

Madrigal: Clear Path Ahead

MDGL announced NAFLD data in January. The 2018 NASH data has some predictive value for the phase 3 NASH trial.

Madrigal: NASH Data In Q4 Is The Key

CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results.

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Skillsoft

After seeing a sell-off for most of January, two market indexes rose for the fourth day in a row on Wednesday. The S&P 500 Index was up 13.95 points, or 0.31%, while the tech-heavy Nasdaq Composite gained 0.2%.

3 Graham's Lost Formula Stocks to Consider for February

Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50% reduction liver fat. Key study will be MAESTRO-NASH, which will have liver biopsy data. Results for this study expected later in 2022.

Madrigal NASH Data Is Promising, Next Study Is Key For Success

A positive data readout from a phase 3 clinical trial propelled the drugmaker's shares higher.

Why Madrigal Pharmaceuticals Stock Briefly Spiked Today

Madrigal Pharmaceuticals Inc MDGL has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom.  [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health

The stock price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) increased by over 14% pre-market today. This is why it happened.

Madrigal Pharmaceuticals (MDGL) Stock: Why The Price Jumped Up Today

Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom:

Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022.

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st

Back in November, Madrigal presented superb data for the open-label portion of its Phase 3 MAESTRO-NAFLD-1 trial. Next month, the company is poised to release additional data for the blinded segment of the aforesaid study.

Madrigal: Powerful Catalyst Approaching

Intercept Pharma

Novavax

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

3 Biotech Stocks With Major Catalysts in January

The stock price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) increased by 2.95% in the previous trading session. This is why it happened.

Madrigal Pharmaceuticals Stock (MDGL): Why The Price Increased

Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Madrigal announced data at AASLD that was published earlier. They have their most important catalyst coming up.

Madrigal: Major Catalyst Coming Up

Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD's upcoming The Liver Meeting® 2021 Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD's upcoming The Liver Meeting® 2021

Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results

In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation's Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments.

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need, announced today that Dr. Robert

Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer

Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks

CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT04951219). MAESTRO-NAFLD-1 is an ongoing 52-week ~1200 patient Phase 3 non-invasive, multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty liver disease (NAFLD), presumed NASH. The study is due to complete later this year with measures of safety and efficacy including reduction in imaging and biomarker measures of NASH, as well as the lowering of LDL-cholesterol and other atherogenic lipids.

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH coupled with safety data from MAESTRO-NAFLD-1, an additional large Phase 3 study, are expected to support the planned Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the US Food and Drug Administration (FDA). Madrigal will continue to enroll additional patients beyond those required for accelerated approval to provide for the clinical outcomes portion of the MAESTRO-NASH Phase 3 clinical trial of resmetirom.

News for Madrigal Pharmaceuticals Stock (MDGL)